Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Tomassi

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|May 19, 2018
Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma MultiformeFrancesco Merlino, Simona Daniele, Valeria La Pietra, et al.
Archiv Der Pharmazie|December 19, 2023
A combined approach of structure-based virtual screening and NMR to interrupt the PD-1/PD-L1 axis: Biphenyl-benzimidazole containing compounds as novel PD-L1 inhibitorsGreta Donati, Monica Viviano, Vincenzo Maria D'Amore, et al.
European Journal of Medicinal Chemistry|May 7, 2022
Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular modelsMartina Menna, Francesco Fiorentino, Biagina Marrocco, et al.
European Journal of Medicinal Chemistry|September 30, 2024
Comprehensive structural investigation of a potent and selective CXCR4 antagonist via crosslink modificationAnna Maria Trotta, Vincenzo Mazzarella, Michele Roggia, et al.
European Journal of Medicinal Chemistry|July 25, 2024
Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sitesAnna Maria Trotta, Stefano Tomassi, Gaetana Di Maiolo, et al.
Journal of Medicinal Chemistry|August 15, 2015
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design ApproachJulian Engel, André Richters, Matthäus Getlik, et al.
Journal of Medicinal Chemistry|May 5, 2026
Development of High-Affinity CHD1 Chromodomain InhibitorsHolger Greschik, Florian Friedrich, Ludwig Seifert, et al.
Oncotarget|June 8, 2018
Combined HAT/EZH2 modulation leads to cancer-selective cell deathFrancesca Petraglia, Abhishek A Singh, Vincenzo Carafa, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|May 19, 2018
Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma MultiformeFrancesco Merlino, Simona Daniele, Valeria La Pietra, et al.
Archiv Der Pharmazie|December 19, 2023
A combined approach of structure-based virtual screening and NMR to interrupt the PD-1/PD-L1 axis: Biphenyl-benzimidazole containing compounds as novel PD-L1 inhibitorsGreta Donati, Monica Viviano, Vincenzo Maria D'Amore, et al.
European Journal of Medicinal Chemistry|May 7, 2022
Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular modelsMartina Menna, Francesco Fiorentino, Biagina Marrocco, et al.
European Journal of Medicinal Chemistry|September 30, 2024
Comprehensive structural investigation of a potent and selective CXCR4 antagonist via crosslink modificationAnna Maria Trotta, Vincenzo Mazzarella, Michele Roggia, et al.
European Journal of Medicinal Chemistry|July 25, 2024
Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sitesAnna Maria Trotta, Stefano Tomassi, Gaetana Di Maiolo, et al.
Journal of Medicinal Chemistry|August 15, 2015
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design ApproachJulian Engel, André Richters, Matthäus Getlik, et al.
Journal of Medicinal Chemistry|May 5, 2026
Development of High-Affinity CHD1 Chromodomain InhibitorsHolger Greschik, Florian Friedrich, Ludwig Seifert, et al.
Oncotarget|June 8, 2018
Combined HAT/EZH2 modulation leads to cancer-selective cell deathFrancesca Petraglia, Abhishek A Singh, Vincenzo Carafa, et al.
Pageof 5